Predictors of Seroconversion of Hepatitis-C Virus in End-Stage Renal Disease Patients
DOI:
https://doi.org/10.36283/PJMD13-1/012Keywords:
Arteriovenous fistula, Renal Dialysis, Hepatitis CAbstract
Background: Chronic kidney disease (CKD) is a significant health challenge globally. Hemodialysis, the primary treatment for CKD, not only sustains lives but also increases the risk of disease transmission, particularly hepatitis C (HCV), with a 48.9% seroconversion rate. This study aimed to identify factors contributing to HCV seroconversion of hemodialysis patients in Karachi.
Methods: A cross-sectional study was conducted at three dialysis units within tertiary care hospitals in Karachi, from June 2022 to June 2023. A total of 141 patients aged between 18 and 65, of any gender, undergoing chronic hemodialysis for a minimum of 6 months, demonstrating good adherence, and possessing comprehensive serological data for HCV (baseline test and follow-up screening) were included. Data was analyzed using SPSS version 27 and a comparison between baseline characteristics and risk factors with seroconversion of HCV was done using independent samples t-test/Chi-square test. A p<0.05 was considered statistically significant.
Results: The patients had a mean age of 33.30±8.04 years. Seroconversion occurred in 14.9% of cases, with 21% testing positive for HCV on PCR. Notably, a higher prevalence of blood transfusion history (p=0.002), surgery history (p=0.001), a family history of HCV (p=0.001), dialysis at multiple centers (p=0.001), and initiating dialysis with an arteriovenous fistula (p=0.015) was observed among HCV-positive patients who underwent seroconversion, in comparison to those who remained HCV-negative.
Conclusion: A history of blood transfusion and surgery, a family history of HCV, dialysis at multiple centers, and initiation of dialysis with arteriovenous fistula are notable predictors for seroconverted positive HCV patients.
References
Anees M, Sarwar N, Ahmad S, Elahii I, Mateen FE. Factors Associated with Seroconversion of Hepatitis C Virus in End Stage Renal Disease Patients. J Coll Physicians Surg Pak. 2021;31(9):1040-1045 DOI: 10.29271/jcpsp.2021.09.1040
Hussain Y, Shahzad A, Azam S, Munawar N. Hepatitis-C and its seroconversion in end stage kidney disease patients on maintenance hemodialysis and factors affecting it. Pak J Med Sci. 2019;35(1):66-70 DOI: 10.12669/pjms.35.1.366
Ismail T, Batool K, Abbasi Z, Khurshid T. Seroconversion of patients undergoing haemodialysis from HCV negative to HCV positive status. J Rawal Med Coll Stude Suppl. 2016;20(S-1):34-37
Garthwaite E, Reddy V, Douthwaite S, Lines S, Tyerman K, Eccles J. Clinical practice guideline management of blood borne viruses within the haemodialysis unit. BMC nephrology. 2019;20:1-22
Kerollos KMN, El-Ameen HA, El Wahed LA, Azoz NMA. Prevalence and seroconversion of hepatitis C among hemodialysis patients in Assiut governorate, Egypt. The Egyptian Journal of Internal Medicine. 2020;32(1):2 DOI: 10.1186/s43162-020-00005-0
Dharmesti NWW, Wibawa IDN, Kandarini Y. Hepatitis C Seroconversion Remains High among Patients with Regular Hemodialysis: Study of Associated Risk Factors. Int J Hepatol. 2022;2022:8109977 DOI: 10.1155/2022/8109977
Fissell RB, Bragg-Gresham JL, Woods JD, Jadoul M, Gillespie B, Hedderwick SA, et al. Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney Int. 2004;65(6):2335-2342 DOI: 10.1111/j.1523-1755.2004.00649.x
Madhavan A, Sachu A, Balakrishnan AK, Vasudevan A, Balakrishnan S, Vasudevapanicker J. Prevalence of hepatitis C among haemodialysis patients in a tertiary care hospital in south India. Iran J Microbiol. 2020;12(6):644-649 DOI: 10.18502/ijm.v12i6.5041
Hinrichsen H, Leimenstoll G, Stegen G, Schrader H, Fölsch UR, Schmidt WE. Prevalence and risk factors of hepatitis C virus infection in haemodialysis patients: a multicentre study in 2796 patients. Gut. 2002;51(3):429-433 DOI: 10.1136/gut.51.3.429
Nguyen DB, Bixler D, Patel PR. Transmission of hepatitis C virus in the dialysis setting and strategies for its prevention. Semin Dial. 2019;32(2):127-134 DOI: 10.1111/sdi.12761
Sayiner M, Golabi P, Younossi ZM. Disease burden of hepatocellular carcinoma: a global perspective. Digestive diseases and sciences. 2019;64:910-917
Jafri W, Kamran M. Hepatocellular carcinoma in Asia: a challenging situation. Euroasian Journal of Hepato-Gastroenterology. 2019;9(1):27
Aziz B, Nazar T, Akhlaq S. The frequency of occurrence of Hepatocellular Carcinoma after direct antiviral therapy in Hepatitis C virus patients. Pakistan journal of medical sciences. 2019;35(1):101
Butt N, Anoshia, Khan MA, Akbar A. Effectiveness of Sofosbuvir and Daclatasvir in treatment of Hepatitis-C: An experience of tertiary care hospital in Karachi. Pak J Med Sci. 2021;37(7):2014-2019 DOI: 10.12669/pjms.37.7.4627
Fabrizi F, Martin P, Dixit V, Bunnapradist S, Dulai G. Meta-analysis: Effect of hepatitis C virus infection on mortality in dialysis. Aliment Pharmacol Ther. 2004;20(11-12):1271-1277 DOI: 10.1111/j.1365-2036.2004.02290.x
Xu M, Liu F, Zhao Q, Zhou Y, Zhuang Y, Ji M. Seroprevalence of hepatitis C virus in Jinan, China, 2008–2020. European Journal of Medical Research. 2023;28(1):112 DOI: 10.1186/s40001-023-01063-0
Mostafi M, Jabin M, Chowdhury Z, Khondoker MU, Ali SM, Tamanna R, et al. The outcome of Daclatasvir and low dose Sofosbuvir therapy in end-stage renal disease patients with hepatitis C virus infection. Ukrainian Journal of Nephrology and Dialysis. 2020;0(2(66)) DOI: 10.31450/ukrjnd.2(66).2020.01
Mahmud HM, Siddiqui M, Bashir B, Ali SF, Baloch AA, Masroor M. Hemodialysis patients profile at Dow University of Health Sciences, Karachi. Pakistan. Pak J Med Sci. 2014;30(6):1327-1330 DOI: 10.12669/pjms.306.5364
Bukhari F, Khan A, Mehmood T. Predictors of HCV Seroconversion Among End-stage Renal Disease Patients in Hemodialysis Unit. Bulletin of Pharmaceutical Sciences Assiut. 2020;43(2):199-208
Akhtar S, Nasir JA, Usman M, Sarwar A, Majeed R, Billah B. The prevalence of hepatitis C virus in hemodialysis patients in Pakistan: A systematic review and meta-analysis. PLoS One. 2020;15(5):e0232931 DOI: 10.1371/journal.pone.0232931
Ali Khan R, Ali A, Khan AY. Response of Sofosbuvir and Daclatasvir combination in Chronic Hepatitis C with Hemodialysis Pakistani Patients: A Single Centre Study. Int. j. endorsing health sci. res. 2018;6(4):28-36.https://doi.org/10.29309/TPMJ/2020.27.12.4787
Fissell RB, Bragg-Gresham JL, Woods JD, Jadoul M, Gillespie B, Hedderwick SA, et al. Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: The DOPPS. Kidney International. 2004;65(6):2335-2342 DOI: 10.1111/j.1523-1755.2004.00649.x
Kataruka M, Gupta S, Ramchandran R, Singh M, Dhiman RK, Lal Gupta K. Incidence and Risk Factors for Hepatitis C Virus and Hepatitis B Virus Seroconversion in End-Stage Renal Failure Patients on Maintenance Hemodialysis. Journal of Clinical and Experimental Hepatology. 2020;10(4):316-321 DOI: https://doi.org/10.1016/j.jceh.2019.11.002
Jadoul M, Bieber BA, Martin P, Akiba T, Nwankwo C, Arduino JM, et al. Prevalence, incidence, and risk factors for hepatitis C virus infection in hemodialysis patients. Kidney International. 2019;95(4):939-947 DOI: https://doi.org/10.1016/j.kint.2018.11.038
Mahupe P, Molefe-Baikai OJ, Saleshando G, Rwegerera GM. Prevalence and risk factors for hepatitis b and c among end-stage renal disease patients on hemodialysis in Gaborone, Botswana. Niger J Clin Pract. 2021;24(1):81-88 DOI: 10.4103/njcp.njcp_464_19
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Pakistan Journal of Medicine and Dentistry
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an open-access article distributed under the terms of the CreativeCommons Attribution License (CC BY) 4.0 https://creativecommons.org/licenses/by/4.0/
